Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04288115 · ClinicalTrials.gov registry record · Phase 4
Discontinuation of Levothyroxine Therapy for Patients With Subclinical Hypothyroidism
A Phase 4 study of Subclinical Hypothyroidism, sponsored by VA Office of Research and Development.
- Completed
- Registry status
- Phase 4
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT04288115 is a Phase 4 study of Subclinical Hypothyroidism that has completed, run by VA Office of Research and Development. The registered enrollment target is 52 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04288115, a Phase 4 study of Subclinical Hypothyroidism, has completed, sponsored by VA Office of Research and Development.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators propose the following hypothesis: discontinuation of levothyroxine (LT4) for veterans with subclinical hypothyroidism (SCH) will be feasible, acceptable, and safe and will not negatively affect their Quality of Life (QoL). The investigators aim to evaluate the feasibility of LT4 discontinuation among veterans with SCH and determine the changes in QoL measures, lipids, and adverse events.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Levothyroxine
Study Locations (1)
Arkansas
- Central Arkansas Veterans Healthcare System Eugene J. Towbin Healthcare Center, Little Rock, AR - North Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2021-03-24 |
| Est. Completion | 2022-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04288115
The ClinicalTrials.gov registry entry for NCT04288115 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Subclinical Hypothyroidism appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04288115 reports 1 study location spanning 1 distinct geographic area - top geographies include Arkansas.
Frequently Asked Questions
What is clinical trial NCT04288115 about?
NCT04288115 is a clinical study titled "Discontinuation of Levothyroxine Therapy for Patients With Subclinical Hypothyroidism". The investigators propose the following hypothesis: discontinuation of levothyroxine (LT4) for veterans with subclinical hypothyroidism (SCH) will be feasible, acceptable, and safe and will not negatively affect their Quality of Life (QoL). The investigators aim to evaluate the feasibility of LT4 di...
What is the current status of trial NCT04288115?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 52 participants. The study started on 2021-03-24. Estimated completion is 2022-12-31.
What conditions does trial NCT04288115 study?
This clinical trial studies the following conditions: Subclinical Hypothyroidism.
What interventions are being tested in trial NCT04288115?
The interventions under investigation include: Placebo (OTHER), Levothyroxine (DRUG).
Who is sponsoring clinical trial NCT04288115?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04288115 being conducted?
This trial has 1 study location across Arkansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Subclinical Hypothyroidism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.